Posted May. 31, 2012 at 11:52 a.m.
Chelsea
BeleagueredChelsea Therapeutics now will focus its remaining resources on an orphan drug candidate that has already fallen short of regulatory approval....
Charlotte drug firm's arthritis treatment fails in trial
Post a comment
Print this blog postE-mail blog post
Share
Chelsea
BeleagueredChelsea Therapeutics now will focus its remaining resources on an orphan drug candidate that has already fallen short of regulatory approval....
WRAL Tech Wire any time: Twitter, Facebook
Copyright 2013 MedCity. All rights reserved.Please log in or register to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
Duke's Vivek Wadhwa cracks Time 'Most Influential' list- IBM layoff update: North American cuts climb; mum is word down under
- At last! Sprint 4G service formally launches in Triangle
- Big Blue's layoff total climbs in RTP; North America total surges past 2,800
- Big Blue layoff count nears 2,800 in North America alone
- NC's high-tech job picture improves in May, but ...
- IBM layoff count hits nearly 2,300 across 31 work groups
- NC IDEA: Startup deal flow 'better than it has ever been'
- IBM's job cuts are global, nearing 4,000; most are in U.S.
- CEO fears for future of NC Biofuels Center due to budget cuts